AHMED ELKHANANY to Cyclin-Dependent Kinase 4
This is a "connection" page, showing publications AHMED ELKHANANY has written about Cyclin-Dependent Kinase 4.
Connection Strength
0.504
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
Score: 0.233
-
CDK4/6 Inhibitors in Breast Cancer-Who Should Receive Them? Int J Mol Sci. 2025 Oct 23; 26(21).
Score: 0.225
-
Effect of prior treatments on post-CDK 4/6 inhibitor survival in hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2023 Feb; 197(3):673-681.
Score: 0.046